文献速递新发突发、热带与寄生虫病

巴西亚马逊地区葡萄糖-6-磷酸脱氢酶缺乏症患者中三种替代方案治疗复发性间日疟的安全性与有效性(ALTPRIM)

Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM).
PubMed 文献 · Clin Infect Dis · 2025-01-01

在巴西亚马逊两个中心纳入葡萄糖-6-磷酸脱氢酶缺乏症(G6PDd)合并间日疟患者,随机分为三组:第1组第5天起每日伯氨喹7天(0.5 mg/kg/天),第2组每周伯氨喹8周(0.75 mg/kg/周),第3组每周氯喹12周(5 mg/kg/周);另平行纳入G6PD正常组用氯喹3天加伯氨喹7天。G6PDd共54例,第1组仅2例即因安全性担忧终止。每周伯氨喹组首次给药后第3天血红蛋白下降(Δ血红蛋白=-1.61)大于每周氯喹组(Δ血红蛋白=-0.99),但6个月随访期间有效性更优。结论:将每日伯氨喹推迟至第5天开始未能证明安全;每周氯喹避免首次复发但未阻止后续复发;每周伯氨喹在拉丁美洲患者中安全有效,与东南亚已证明的结果一致。

要点

  • G6PDd患者中将每日伯氨喹推迟至第5天开始未能证明安全,第1组仅入组2例即因安全性担忧终止。
  • 每周伯氨喹组首次给药后第3天血红蛋白下降(Δ血红蛋白=-1.61)大于每周氯喹组(Δ血红蛋白=-0.99),但6个月随访有效性更优。
  • 每周氯喹避免首次复发但未阻止后续复发;每周伯氨喹在拉丁美洲患者中安全有效。

核心结论

  • 将每日伯氨喹推迟至第5天开始,理论上此时疟疾本身所致氧化应激较少、可减轻药物在G6PDd患者中的溶血效应,但未能证明安全。
  • 每周氯喹避免首次复发但未阻止后续复发。
  • 每周伯氨喹在拉丁美洲患者中安全有效,与东南亚已证明的结果一致。

研究设计与样本

  • 2018年至2022年在巴西亚马逊2个中心开展的随机分组研究,G6PDd合并间日疟参与者随机分配至3组。
  • 第1组:第1天至第3天氯喹(CQ)加第5天起每日伯氨喹(PQ)0.5 mg/kg/天共7天。
  • 第2组:每周伯氨喹0.75 mg/kg/周共8周。
  • 第3组:每周氯喹5 mg/kg/周共12周。
  • 另平行纳入G6PD正常参与者组,使用氯喹3天加伯氨喹7天。

主要发现

  • 第1组仅2例参与者,该组因安全性担忧被终止。
  • 每周伯氨喹组首次给药后第3天血红蛋白下降(Δ血红蛋白=-1.61)大于每周氯喹组(Δ血红蛋白=-0.99)。
  • 每周伯氨喹组在6个月随访期间有效性优于每周氯喹组。
  • 每周氯喹避免首次复发但未阻止后续复发。

局限性

  • 第1组仅2例参与者即因安全性担忧被终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Daily primaquine-induced hemolysis is a common cause of complications during Plasmodium vivax malaria treatment in individuals with glucose 6-phosphate dehydrogenase deficiency (G6PDd). Alternative regimens balancing safety and efficacy are needed. METHODS: G6PDd participants with P. vivax malaria from 2 sites in Brazilian Amazon between 2018 and 2022 were randomly allocated to 3 arms that received chloroquine (CQ) from day 1 to day 3 plus (arm 1) a 7-day course of primaquine (PQ) (0.5 mg/kg/day), beginning at day 5; (arm 2) weekly PQ over 8 weeks (0.75 mg/kg/wk); or (arm 3) weekly CQ over 12 weeks (5 mg/kg/wk). A normal-G6PD participants group was also enrolled in parallel using CQ for 3 days plus PQ for 7 days. The primary focus was safety profile; secondary was the number of patients free from the first recurrence until day 180. RESULTS: Fifty-four G6PDd participants were enrolled. There were 2 participants in arm 1, but the arm was halted due to safety concerns. The weekly PQ group presented higher hemoglobin decreases in day 3 after first dose (Δhemoglobin = -1.61) than the weekly CQ group (Δhemoglobin = -0.99), but efficacy was superior over the 6-month follow-up. CONCLUSIONS: Postponing the beginning of daily PQ to day 5, when less oxidative stress related to malaria itself would, in theory, decrease hemolytic effects of the drug in G6PDd patients, was not shown to be safe. Weekly CQ avoiding the first relapse did not stop further relapses. Weekly PQ, as already demonstrated in Southeast Asia, was equally safe and efficacious in patients from Latin America. Clinical Trials Registration. NCT03529396.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Barbosa L, Brito-Sousa J, Nascimento C, et al. Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM). Clin Infect Dis. 2025. PMID: 39785834. doi:10.1093/cid/ciaf007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。